Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Combination With Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma
NCT03937219Phase 3Active, not recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Jun 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, double-blind trial of cabozantinib in renal cell carcinoma (RCC) (2 arms), sponsored by Exelixis, Inc. Primary endpoint: Progression-Free Survival at 32 months. Started Jun 2019; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03937219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03937219.